Effects of combination therapy with bleomycin (NSC-125066) and dibromodulcitol (NSC-104800) on squamous cell carcinoma in man.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000188:drug therapy; D001761:Bleomycin / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D005334:Fever / Q000139:chemically induced; D004376:Galactitol / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007958:Leukocyte Count; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010412:Penile Neoplasms / Q000188:drug therapy; D012871:Skin Diseases / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy; D013402:Sugar Alcohols / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014839:Vomiting / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D013402:Sugar Alcohols; D001761:Bleomycin; D004376:Galactitol